Neurocrine wins FDA OK for first-in-class CAH drug

17 December 2024

Neurocrine Biosciences (Nasdaq: NBIX) has secured US Food and Drug Administration approval for Crenessity (crinecerfont).

The first-in-class oral treatment for classic congenital adrenal hyperplasia (CAH) will become the first major advancement for CAH patients in over 70 years, and comes nearly two weeks ahead of the agency’s target date.

The rare genetic disorder, which affects about 30,000 individuals in the USA, causes an imbalance between cortisol and androgen hormones, leading to excess production of androgens like testosterone.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical